Penumbra, Inc.
Penumbra, Inc.
Your view on PEN
Overview
What the company does, where it operates, and who runs it.
About Penumbra, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Adam Elsesser
- Headquarters
- One Penumbra Place, Alameda, CA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Adam Elsesser
- Headquarters
- One Penumbra Place, Alameda, CA, US
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally.
The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands.
It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names.
In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands.
The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Penumbra, Inc. from FRC's valuation model, read against the market price. PEN last traded at $321.72, 80.6× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Penumbra, Inc.. Starting points for Penumbra, Inc.: P/E 80.6, EPS $3.98, beta 0.69 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Penumbra, Inc.. Penumbra, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Penumbra, Inc.. Trailing twelve-month EPS for Penumbra, Inc. stands at $3.98. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$320.00
Median
$320.00
High
$320.00
Average target
Analyst Ratings
- Strong Buy0
- Buy9
- Hold13
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.44 | $1.37 | $4.76 | $6.01 |
| Low estimate | $1.41 | $1.30 | $4.58 | $5.35 |
| High estimate | $1.48 | $1.46 | $4.94 | $6.67 |
| No. of analysts | 5 | 5 | 6 | 6 |
| Year-ago EPS | $1.20 | $0.82 | $4.52 | — |
| Growth | +20.4% | +66.8% | +5.3% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $430.41M | $424.16M | $1.60B | $1.82B |
| Low estimate | $417.32M | $420.17M | $1.57B | $1.79B |
| High estimate | $442.51M | $426.72M | $1.62B | $1.84B |
| No. of analysts | 8 | 4 | 6 | 9 |
| Year-ago revenue | $385.38M | $374.76M | $1.40B | — |
| Growth | +11.7% | +13.2% | +14.0% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Penumbra, Inc.. Penumbra, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Penumbra, Inc. valued side by side against its closest peers. Penumbra, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Penumbra, Inc., and how their positions are changing. At a $12.68B market value, institutional positions materially move Penumbra, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Penumbra, Inc. executives and directors. Shares of Penumbra, Inc. have traded between $221.26 and $310.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Penumbra, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Penumbra, Inc.. Coverage tracks Penumbra, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Penumbra, Inc.